A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
==================================================================================================================================================

* Moshe C. Ornstein
* Laura S. Wood
* Brian P. Hobbs
* Kimberly D. Allman
* Allison Martin
* Michael Bevan
* Timothy D. Gilligan
* Jorge A. Garcia
* Brian I. Rini